Trials / Completed
CompletedNCT03430479
Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Kyoto Breast Cancer Research Network · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety and efficacy of anti PD-1 antibody with radiation therapy in patients with HER2-negative metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cohort A | Radiation + Nivolumab + hormone therapy |
Timeline
- Start date
- 2017-06-22
- Primary completion
- 2018-11-30
- Completion
- 2021-04-01
- First posted
- 2018-02-13
- Last updated
- 2023-01-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03430479. Inclusion in this directory is not an endorsement.